Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
Gayathri Nagaraj, MBBS
Assistant Professor, Medicine
School of Medicine
Publications    Scholarly Journals--Published
  • G Nagaraj, CX Ma. Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: challenges and considerations. J Natl Compr Canc Netw 2013 Mar 1; 11(3):246-51. ( 3/2013 )
  • J Subramanian, T Regenbogen, G Nagaraj, A Lane, S Devarakonda, G Zhou, R Govindan. Review of ongoing clinical trials in non-small-cell lung cancer: A status report for 2012 from the clinicaltrials.gov website. J Thorac Oncol. 2013 Mar 8. [Epub ahead of print]. ( 3/2013 )
  • G Nagaraj, MJ Ellis, CX Ma. Commentary. The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept. Oncology (Williston Park). 2012 Aug;26(8):696-7, 700. ( 8/2012 )
  • LS Bachegowda, G Nagaraj, PD Grivas, L Chen, E Choi, M Styler. Two “childhood” malignancies in an elderly woman: A case report and discussion. Med Oncol. 2010 Sep;27(3):876-9. ( 9/2010 )
  • S. Kalghati, G Fridman, G Nagaraj, M Peddinghaus, M Balasubramanian, A Brooks, A Gustole, A Vasiletse, A Fridman, G Friedman. Mechanism of blood coagulation by non-thermal atmospheric pressure dielectric barrier discharge plasma. IEEE transaction on plasma science. Oct 2007, vol 35 issue 5, pages 1559-1566. ( 10/2007 )
  • Cho May, Wang-Gillam Andrea, Myerson Robert, Gao Feng, Strasberg Steven, . . . Tan Benjamin R. (2015). A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB: The Official Journal of the International Hepato Pacreato Biliary Association, 17(7), 587-593. ( 0/2015 - Present ) Link...
    Objectives Adjuvant gemcitabine with or without chemoradiation is a standard therapeutic option for patients with resected pancreatic cancer. The feasibility and toxicity of gemcitabine with docetaxel before and after 5-fluorouracil (5 FU)-based chemoradiation in the adjuvant pancreatic and biliary cancer setting were investigated. Methods After a curative-intent resection, eligible patients with pancreaticobiliary cancers were treated with two cycles of gemcitabine and docetaxel followed by 5 FU-based chemoradiation. Four weeks after completing chemoradiation, two cycles of gemcitabine and docetaxel were administered. The primary endpoint was the incidence of severe toxicities. Secondary endpoints included disease-free survival ( DFS) and overall survival ( OS). Results Fifty patients with pancreaticobiliary cancers were enrolled. Twenty-nine patients had pancreatic cancer whereas 21 patients had biliary tract or ampullary cancers. There was one death as a result of pneumonia, and 15% of patients experienced grade 3 or greater non-haematological toxicities. The median DFS and OS for patients with pancreatic cancer were 9.6 and 17 months, respectively, and for those with resected biliary tract cancer were 12 and 23 months, respectively. Conclusions This combination of gemcitabine and docetaxel with chemoradiation is feasible and tolerable in the adjuvant setting. Future studies utilizing a different gemcitabine/taxane combination and schedule may be appropriate in the adjuvant treatment of both pancreatic cancer and biliary tumours. [ABSTRACT FROM AUTHOR] Copyright of HPB: The Official Journal of the International Hepato Pacreato Biliary Association is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
  • Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G F, & Govindan R. (2013). Review of Ongoing Clinical Trials in Non-Small-Cell Lung Cancer A Status Report for 2012 from the ClinicalTrialsgov Web Site. Journal of Thoracic Oncology, 8(7), 860-865. ( 7/2013 - Present ) Link...
    Introduction: Clinical research in non-small-cell lung cancer (NSCLC) is a rapidly evolving field. In an effort to identify the current trends in lung cancer clinical research, we reviewed ongoing clinical trials in NSCLC listed in the registry in 2012, and we also compared this data to a similar survey conducted by us in 2009. Methods: The Web site's advanced search function was used to search for the term non-small cell lung cancer. The search was further refined by using the following options from the search page drop-down menu, open studies and interventional. Studies with non-NSCLC tumor histologies and pediatric studies were excluded. Results: Of the 477 trials included in the analysis, 105 (22.0%) were phase I, 223 phase II (46.8%), and 63 phase III trials (13.2%). When compared with data from 2009, university-sponsored trials decreased in number (45.4%-34.2%; p < 0.001) whereas industry-sponsored trials remained almost the same. There was a significant increase in trials conducted exclusively outside of the United States (35.9%-48.8%; p = 0.001). The number of studies with locations in China (61, 12.8%) was second only to that in the United States (244, 51.2%). Studies reporting biomarker analysis increased significantly from 37.5% to 49.1% in 2012 (p < 0.001). Biomarker-based patient selection also increased significantly from 7.9% to 25.8% (p < 0.001). Targeted therapies were evaluated in 70.6% of phase I/II and II trials, and the most common class of targeted agent studied was epidermal growth factor receptor tyrosine kinase inhibitors (38.0%). Prespecified accrual times were observed to increase when compared with data reported in 2009, especially among industry-sponsored studies. Conclusions: Our survey identified major changes in lung cancer clinical research since 2009. Almost half of all studies registered at the Web site are being conducted outside the United States, and several novel molecularly targeted agents are being evaluated in the treatment of patients with NSCLC. More importantly, we identified a threefold increase in the number of studies that perform biomarker testing to determine patient selection over the last 3 years.
  • Nagaraj G, & Ma C X. (2013). Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations. Journal of the National Comprehensive Cancer Network, 11(3), 246-251. ( 3/2013 - Present )
    Decisions regarding adjuvant chemotherapy for patients with estrogen receptor (ER) positive, HER2-negative, lymph node negative breast cancer have traditionally relied on clinical and pathologic parameters. However, the molecular heterogeneity and the complex tumor genome demand more sophisticated approaches to the problem. Several multigene-based assays have been developed to better prognosticate the risk of recurrence and death and predict benefit of therapy in this patient population. Oncologists are often faced with the challenge of incorporating these various complex genome-based biomarkers along with the traditional biomarkers in clinical decision-making. The NCCN Clinical Practice Guidelines in Oncology for Breast Cancer are helpful in providing a general recommendation. However, uncertainty remains in the absence of definitive data for various clinical scenarios. This case report describes a postmenopausal woman with stage I breast cancer that is low-grade and ER-rich, and has an intermediate Oncotype DX recurrence score of 28. (JNCCN 2013;11:246-251)
  Books and Chapters
  • G. Nagaraj. Introduction to Oncology. In A.F. Cashen and B.A. Van Tine, The Washington Manual Hematology and Oncology Subspecialty Consult, 3rd Edition. Lippincott Williams & Wilkins 2012. ( 0/2012 )
  • G. Nagaraj. Cancer of Unknown Primary. In A.F. Cashen and B.A. Van Tine, The Washington Manual Hematology and Oncology Subspecialty Consult, 3rd Edition. Lippincott Williams & Wilkins 2012. ( 0/2012 )
  • Y.H. Chia, G. Nagaraj, C. Sanchez. Breast Cancer. In A.F. Cashen and B.A. Van Tine, The Washington Manual Hematology and Oncology Subspecialty Consult, 3rd Edition. Lippincott Williams & Wilkins 2012. ( 0/2012 )